Researchers describe a real-world study of acoramidis use in adults with ATTR heart disease
The ACO-REAL study will follow about 2,000 adults for roughly 12 months in European routine care settings.
Moderate evidenceHuman studySome caution advised
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The researchers created ACO-REAL to complement earlier phase 3 trial findings for acoramidis (ATTRibute-CM). Their goal is to understand how acoramidis is used in everyday care and how patients’ disease course and day-to-day functioning change during follow-up.
Because the study is non-interventional, it is designed to observe what happens in clinical practice. It will track demographics and disease characteristics at the start, describe treatment changes (including switching to acoramidis), and evaluate safety and several measures of cardiac function and patient-reported outcomes.
What the study looked at
The study question is how adults with ATTR-CM who are starting acoramidis look and are treated in real-world European healthcare settings, and what safety and clinical course measures are observed over an observational period of around 12 months. Design details include a prospective, non-interventional, multicenter approach with approximately 2,000 adults with wild-type or variant ATTR-CM across 21 European countries.
What the trial found
The provided abstract does not report study results. It describes the study rationale and design, including planned assessments of demographics, disease characteristics, treatment patterns (such as adherence, persistence, and reasons for treatment modification), safety, cardiac function, functional capacity, health status (including NYHA class and 6-minute walk distance), quality of life questionnaires, and healthcare resource utilization, with exploratory descriptive analyses planned.
Who this is relevant to
These study plans may be most relevant to adults with transthyretin amyloid cardiomyopathy (wild-type or variant) who begin acoramidis in European routine clinical settings, and to researchers or clinicians interested in real-world safety, treatment patterns, and patient-reported outcomes. The design and planned measurements do not substitute for controlled evidence of effectiveness, and results (once published) would still reflect observational practice rather than guaranteed causal effects. This article itself does not provide findings, so its direct applicability to patient outcomes is limited until results are reported.
Why it matters
Real-world data can help show how an approved treatment is used outside the tightly controlled conditions of clinical trials, and can highlight patterns of care and safety signals in broader patient groups. However, this particular publication focuses on the design of an ongoing study, so it does not by itself provide evidence about effectiveness; it is meant to support future observational findings in routine care settings.
Limitations & evidence assessment
This article does not provide results—only rationale and study design—so it cannot answer whether acoramidis improves outcomes or how frequently side effects occur. Even when results are available, a non-interventional observational design limits conclusions about cause and effect, since participants are not assigned treatments by the study. The abstract provides no detailed plans for how key confounders will be handled (unknown from the provided text). Follow-up is planned for about 12 months, which may not capture longer-term outcomes.
Why this evidence level: Clinical trial without confirmed randomization details in the available metadata.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
Cardiology and Therapy · 2026 · DOI: 10.1007/s40119-026-00461-9
This review analyzed human studies comparing two treatments given before surgery for locally advanced esophageal or esophagogastric junction adenocarcinoma: FLOT chemotherapy and CROSS chemoradiotherapy. The pooled estimate favored FLOT for overall survival, but the groups had similar three-year survival, tumor response, surgical margins, and several major perioperative outcomes.
A systematic review examined whether Passiflora edulis, commonly known as passion fruit, is linked with lower blood pressure. It included six preclinical studies and two human trials; the animal and laboratory findings were generally more extensive than the human evidence. The authors reported possible blood-pressure reductions but emphasized that the human studies were small, varied in the extracts used, and short in duration.
Researchers studied 96 people with high-risk, locally advanced rectal cancer in a single-center phase II clinical trial. The treatment combined chemotherapy, short-course radiation, and a targeted drug selected for each study cohort. Overall, 40% had a complete response, but the study did not establish how this approach compares with other treatments.
